SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
---------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) September 3, 1996
------------------------------
SPARTA PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-23076 56-1755527
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
111 Rock Rd. Horsham, PA 19044
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (215) 442-1700
----------------------------
<PAGE>
ITEM 1. Changes in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant.
Not applicable.
Item 5. Other Events
On September 3, 1996, Sparta Pharmaceuticals, Inc. issued a press
release filed as Exhibit 99.8 hereto announcing the commencement of
its first U.S. clinical trial with RII retinamide.
Item 6. Resignations of Registrant's Directors.
Not applicable.
Item 7. Financial Statements and Exhibits.
(a) Financial Statements of Sparta Pharmaceuticals, Inc.
-----------------------------------------------------
Not applicable.
(b) Pro Forma Financial Information
-------------------------------
Not applicable
(c) Exhibits
--------
99.8 -- Press Release, dated as of September 3, 1996, announcing
the commencement of Sparta's first U.S. clinical trial
with RII retinamide.
<PAGE>
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this amendment to be signed on its behalf by the
undersigned thereunto duly authorized.
Sparta Pharmaceuticals, Inc.
September 9, 1996 By: /s/ Jerry B. Hook
- -------------------------- ------------------------
Date Jerry B. Hook, Ph.D. President,
Chief Executive Officer & Director
(principal executive officer)
<PAGE>
EXHIBIT INDEX
- --------------------------------------------------------------------------------
Exhibit
Number Description Page
- ------ ------------ ----
99.8 -- Press Release, dated as of September 3, 5
1996, announcing the commencement of Sparta's
first U.S. clinical trial with RII retinamide.
